News & Events

The Firm represented the underwriters, Credit Suisse, Deutsche Bank Securities, J.P. Morgan and ICBC International, in connection with the initial public offering and listing on the NASDAQ Global Select Market of common shares of Athenex Inc. (“Athenex”). The offering of 6,900,000 shares of common stock raised US$75.9 million of gross proceeds to Athenex including full exercise of the greenshoe. Athenex’s common stock is traded on the NASDAQ Global Select Market under the symbol “ATNX.”

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Based in Buffalo, New York, Athenex has established global operations in the U.S. and China across the pharmaceutical value chain.

The Simpson Thacher team for the transaction includes Chris Lin, Daniel Fertig, Brian Mathes and Cherrie Zhang (Capital Markets — Hong Kong); Tony Rim (Capital Markets — NY); Noah Leibowitz, Jeffrey Ostrow, Linda Nyberg and Amber Harezlak (Intellectual Property); Katherine Helm (FDA Regulatory); Adam Goldberg (Compliance); and Pierce Pandolph (Tax).